Windtree Therapeutics, a Nasdaq-listed biotech firm, plans to purchase up to $700 million in BNB, a leading cryptocurrency, following its recent all-time high price. The company is raising $520 million to facilitate these acquisitions, building on a previous plan to acquire $200 million in BNB. Windtree has partnered with Kraken for asset custody, explaining that securing additional funding is crucial to their strategy. As the fifth-largest digital coin, BNB boasts a market cap of $106.9 billion and hit a new peak of $808 recently. This trend reflects a growing movement of publicly traded companies investing in cryptocurrencies—beyond Bitcoin—to enhance their balance sheets, with Windtree's stock seeing a notable increase of 162% over the past month despite a recent dip of about 5%. This aligns with initiatives from other firms like Nano Labs, which recently announced plans to buy $1 billion in BNB.

Source 🔗